Curasight (CURAS) | Spotlight

Curasight is active in the pharmaceutical industry. The company specializes in research and development of various drug candidates. The product portfolio includes, for example, research and development within Positron Emission Tomography (PET) and related ancillary services. The business is operating with the largest presence within Scandinavia. Curasight is headquartered in Copenhagen.

Quotes for Curasight A/S

Right Now

+/-: 0.07
%: 1,43%
Latest: 4.96
High: 4.98
Low: 4.8
Volume: 4 658
Turnover (DKK): 22 809
Market Value (MDKK): 227,5
Time (Latest trade): 2025-09-16 09:39

Board

CEO

Ulrich Krasilnikoff

Chairperson of the Board

Kirsten Drejer

Board

Andreas Kjær
Charlotte Vedel
Lars Trolle
Ulrich Krasilnikoff

News

2025-09-03 21:51:44 Transaction with shares in Curasight A/S made by managerial employee
2025-08-28 07:00:00 Half-year report Q2 2025
2025-08-26 07:05:00 Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT[®] in brain cancer patients
2025-06-23 17:35:00 Curasight A/S announces outcome of T03 warrant exercise
2025-06-18 17:35:00 Curasight A/S submits Clinical Trial Application for Phase 1 trial with uTREAT[®] in brain cancer patients

News agencies

2025-08-29 12:40:15 MarketWire: Dansk biotekselskab runder begivenhedsrigt halvår af: EMA-godkendelse kronen på værket
2025-08-28 07:10:45 Finwire: Curasight rapporterar ökad rörelseförlust
2025-06-24 07:12:29 Finwire: Curasight rapporterar marginellt utnyttjande av teckningsoptioner
2025-06-19 08:48:52 Finwire: Curasight har lämnat in ansökan till EMA om fas 1-studie
2025-06-02 08:20:17 Finwire: Curasight genomför riktad emission till garanter - utspädning på 2,1 procent

Analysis

2025-09-02 SEB Research: Curasight: Good progress on uTRACE ph2, uTREAT ph1 - SEB
2025-05-21 Redeye: Curasight: 47% subscription in the rights issue - Redeye
2025-04-29 Redeye: Curasight Q1: Securing runway to readouts - Redeye
2025-04-07 SEB Research: Curasight: Rights issue brings new investors, including partner Curium - SEB
2025-04-07 Redeye: Curasight: DKK100m rights issue announced - Redeye

Videos

Largest Owners

Name	Capital %	Votes %	Date
Curium International Trading B.V	19,60	19,60	2025-08-04
Andreas Kjær	15,96	15,96	2025-08-04
UK Curacap ApS	11,62	11,62	2025-08-04
Carsten Haagen Nielsen	5,25	5,25	2025-08-04
Pentwater Capital Management LP	5,18	5,18	2025-08-04
Nordnet Bank AB	2,06	2,06	2025-08-04
Jacob Madsen	2,04	2,04	2025-08-04
Avanza Bank AB	1,58	1,58	2025-08-04
Chr. Olesen Holding A/S	1,54	1,54	2025-08-04
Lars Trolle	1,29	1,29	2025-09-01

Holdings by Modular Finance AB. Compiled and processed data from various sources, including VP Securities, Morningstar and The Danish Financial Supervisory Authority (Finanstilsynet)

Insider trading

*Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

Curasight A/S

Quotes for Curasight A/S

Right Now

Board

News

News agencies

Analysis

Videos

Curasight - Providing answers for cancer patients

Largest Owners

Insider trading

Key Numbers

Upcoming reports

Annual reports, prospectus etc.